<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parlane, N.A.</style></author><author><style face="normal" font="default" size="100%">Compton, B.J.</style></author><author><style face="normal" font="default" size="100%">Hayman, C.M.</style></author><author><style face="normal" font="default" size="100%">Painter, G.F.</style></author><author><style face="normal" font="default" size="100%">Basaraba, R.J.</style></author><author><style face="normal" font="default" size="100%">Heiser, A.</style></author><author><style face="normal" font="default" size="100%">Buddle, B.M.</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Carbohydrate Chemistry</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.scopus.com/inward/record.url?eid=2-s2.0-84355166213&partnerID=40&md5=d96c28a54abad25850c30f337774eda4</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">580-588</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Mycobacterium bovis infects a wide range of hosts, including domestic livestock, wildlife, and humans. Development of an effective vaccine protecting against bovine tuberculosis would provide a cost-effective tuberculosis control strategy. The objective of this study was to investigate the ability of phosphatidylinositol di-mannoside (PIM2) and its derivatives to modulate cell-mediated immunity in vivo in a bovine tuberculosis mouse model in response to a relevant antigen, namely a fusion protein of mycobacterial proteins Ag85A and ESAT-6. The addition of synthetic PIM2 to the vaccine resulted in a significant reduction in lung bacterial counts and a cytokine profile indicating a Th 1 type immune response. The addition of the other PIM2 derivatives to the vaccine or the fusion protein alone did not result in reduced lung bacterial counts; moreover, the addition of PIM2ME appeared to negate the induction of an antigen-specific interferon-γ response and protection against tuberculosis. In conclusion, this study provides further evidence that PIMs can function as potent adjuvants for protein or sub-unit vaccines, but subtle structural differences among PIMs can markedly alter the type of immune response induced. © 2011 Elsevier Ltd.</style></abstract></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wedlock, D.N.</style></author><author><style face="normal" font="default" size="100%">Denis, M.</style></author><author><style face="normal" font="default" size="100%">Painter, G.F.</style></author><author><style face="normal" font="default" size="100%">Ainge, G.D.</style></author><author><style face="normal" font="default" size="100%">Vordermeier, H.M.</style></author><author><style face="normal" font="default" size="100%">Hewinson, R.G.</style></author><author><style face="normal" font="default" size="100%">Buddle, B.M.</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Carbohydrate Chemistry</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical and Vaccine Immunology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adjuvants</style></keyword><keyword><style  face="normal" font="default" size="100%">animal</style></keyword><keyword><style  face="normal" font="default" size="100%">animal disease</style></keyword><keyword><style  face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style  face="normal" font="default" size="100%">animal model</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">antibody response</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">bacterial protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">bacterial vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">BCG vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Bovine</style></keyword><keyword><style  face="normal" font="default" size="100%">cattle</style></keyword><keyword><style  face="normal" font="default" size="100%">cattle disease</style></keyword><keyword><style  face="normal" font="default" size="100%">combination chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style  face="normal" font="default" size="100%">cytokine production</style></keyword><keyword><style  face="normal" font="default" size="100%">dimethyldioctadecylammonium bromide</style></keyword><keyword><style  face="normal" font="default" size="100%">dose response</style></keyword><keyword><style  face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style  face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style  face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style  face="normal" font="default" size="100%">enzyme linked immunospot assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">female</style></keyword><keyword><style  face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">immune response</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunologic</style></keyword><keyword><style  face="normal" font="default" size="100%">immunological adjuvant</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">immunosuppressive treatment</style></keyword><keyword><style  face="normal" font="default" size="100%">interleukin 10</style></keyword><keyword><style  face="normal" font="default" size="100%">interleukin 12</style></keyword><keyword><style  face="normal" font="default" size="100%">lipopeptide</style></keyword><keyword><style  face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">mycobacterial protein vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium</style></keyword><keyword><style  face="normal" font="default" size="100%">mycobacterium bovis</style></keyword><keyword><style  face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style  face="normal" font="default" size="100%">paratuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">phosphatidylinositol mannoside 2</style></keyword><keyword><style  face="normal" font="default" size="100%">phosphoryl lipid A</style></keyword><keyword><style  face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style  face="normal" font="default" size="100%">toll like receptor 2</style></keyword><keyword><style  face="normal" font="default" size="100%">tuberculin test</style></keyword><keyword><style  face="normal" font="default" size="100%">tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Tuberculosis Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.scopus.com/inward/record.url?eid=2-s2.0-46249095305&partnerID=40&md5=02a87a0ce66c532ee89e31503292874f</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">765-772</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Current efforts are aimed at optimizing the protective efficacy of Mycobacterium bovis BCG by the use of vaccine combinations. We have recently demonstrated that the protection afforded by BCG alone is enhanced by vaccinating cattle with a combination of vaccines comprising BCG and a protein tuberculosis vaccine, namely, culture filtrate proteins (CFPs) from M. bovis plus an adjuvant. In the current study, three different adjuvant systems were compared. The CFP was formulated with a depot adjuvant, dimethyldioctadecyl ammonium bromide (DDA), together with one of three different immunostimulants: monophosphoryl lipid A (MPL), a synthetic mycobacterial phosphatidylinositol mannoside-2 (PIM2), and a synthetic lipopeptide (Pam3Cys-SKKKK [Pam 3CSK4]). Groups of cattle (n = 10/group) were vaccinated with BCG-CFP-DDAPIM2, BCG-CFP-DDA-MPL, or BCG-CFP-DDA-Pam3CSK 4. Two additional groups (n = 10) were vaccinated with BCG alone or BCG-adjuvant (DDA-MPL), and a control group was left unvaccinated. Protection was assessed by challenging the cattle intratracheally with M. bovis. Groups of cattle vaccinated with BCG-CFP-DDA-PIM2, BCG-CFP-DDA-MPL, BCG-CFP-DDA-Pam 3CSK4, and BCG alone showed significant reductions in three, three, five, and three pathological and microbiological disease parameters, respectively, compared to the results for the nonvaccinated group. Vaccination with the combination of BCG and the DDA-MPL adjuvant alone abrogated the protection conferred by BCG alone. The profiling of cytokine gene expression following vaccination, prior to challenge, did not illuminate significant differences which could explain the latter result. Vaccination of cattle with a combination of BCG and protein tuberculosis vaccine enhances protection against tuberculosis. Copyright © 2008, American Society for Microbiology. All Rights Reserved.</style></abstract></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parlane, N.A.</style></author><author><style face="normal" font="default" size="100%">Denis, M.</style></author><author><style face="normal" font="default" size="100%">Severn, W.B.</style></author><author><style face="normal" font="default" size="100%">Skinner, M.A.</style></author><author><style face="normal" font="default" size="100%">Painter, G.F.</style></author><author><style face="normal" font="default" size="100%">La Flamme, A.C.</style></author><author><style face="normal" font="default" size="100%">Ainge, G.D.</style></author><author><style face="normal" font="default" size="100%">Larsen, D.S.</style></author><author><style face="normal" font="default" size="100%">Buddle, B.M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phosphatidylinositol mannosides are efficient mucosal adjuvants</style></title><secondary-title><style face="normal" font="default" size="100%">Immunological Investigations</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">2</style></keyword><keyword><style  face="normal" font="default" size="100%">2 di o palmitoylglycero 3 phosphoryl)inositol</style></keyword><keyword><style  face="normal" font="default" size="100%">2 o (alpha dextro mannopyranosyl) 6 o [(dextro mannopyranosyl(1-6) alpha dextro mannopyranosyl(1-6) alpha dextro mannopyranosyl] 1 o (1</style></keyword><keyword><style  face="normal" font="default" size="100%">6 (di o alpha dextro mannopyranosyl) 1 o (1</style></keyword><keyword><style  face="normal" font="default" size="100%">Adjuvants</style></keyword><keyword><style  face="normal" font="default" size="100%">Administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Adoptive Transfer</style></keyword><keyword><style  face="normal" font="default" size="100%">animal cell</style></keyword><keyword><style  face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">cellular immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">cytokine release</style></keyword><keyword><style  face="normal" font="default" size="100%">dendritic cell</style></keyword><keyword><style  face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">female</style></keyword><keyword><style  face="normal" font="default" size="100%">Freund adjuvant</style></keyword><keyword><style  face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style  face="normal" font="default" size="100%">immune response</style></keyword><keyword><style  face="normal" font="default" size="100%">immunization</style></keyword><keyword><style  face="normal" font="default" size="100%">immunogenicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunologic</style></keyword><keyword><style  face="normal" font="default" size="100%">immunological adjuvant</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon Type II</style></keyword><keyword><style  face="normal" font="default" size="100%">interleukin 12</style></keyword><keyword><style  face="normal" font="default" size="100%">interleukin 4</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-12</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style  face="normal" font="default" size="100%">Intranasal</style></keyword><keyword><style  face="normal" font="default" size="100%">mannoside</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">mouse</style></keyword><keyword><style  face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium</style></keyword><keyword><style  face="normal" font="default" size="100%">mycobacterium bovis</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style  face="normal" font="default" size="100%">Oral</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphatidylinositols</style></keyword><keyword><style  face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style  face="normal" font="default" size="100%">T lymphocyte</style></keyword><keyword><style  face="normal" font="default" size="100%">Th1 cell</style></keyword><keyword><style  face="normal" font="default" size="100%">Transgenic</style></keyword><keyword><style  face="normal" font="default" size="100%">transgenic mouse</style></keyword><keyword><style  face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.scopus.com/inward/record.url?eid=2-s2.0-40049088627&partnerID=40&md5=92a06598353f6b57619f51df6fcb0e08</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">129-142</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The development of defined sub-unit vaccines requires the inclusion in the vaccine of an immunological adjuvant. The most important property of adjuvants for vaccines aimed at inducing optimal protection against intracellular bacteria such as Mycobacterium tuberculosis or M. bovis is the ability to enhance cell-mediated immunity, specifically Th1 responses. In this paper, we describe a system where transgenic mice expressing a high proportion of T cells specific for an ovalbumin (OVA) peptide are used to assess the ability of a novel class of adjuvants to positively modulate cell-mediated immune responses. Defined fractions containing purified native or synthetic phosphatidylinositol mannosides (PIMs) from mycobacteria were assessed for their adjuvant activities in response to the model antigen (OVA). Purified PIM preparations given to mice with OVA by the subcutaneous route were shown to elicit an enhanced release of interferon-gamma (IFN-γ) in cellular responses to OVA peptide in vitro. Very little interleukin-4 (IL-4) was released by cells from mice immunized with PIMs and OVA, whereas cells from animals immunized with complete Freund's adjuvant (CFA) and OVA released IL-4 as well as IFN-γ. Synthetic preparations of PIM2 and PIM4 also acted as adjuvants in the mouse model studied. In addition, PIM preparations were shown to generate an efficient cell-mediated immune response to OVA, when the antigen/adjuvant preparations were administered via the oral route or intranasal route. PIM preparations elicited substantial release of interleukin-12 (IL-12) from dendritic cells (DCs). These data suggest that purified or synthetic PIMs act as adjuvants when administered at mucosal surfaces and represent a new class of adjuvants for mucosal immunization against intracellular pathogens. Copyright © Informa Healthcare USA, Inc.</style></abstract></record></records></xml>
